Drugs in MeSH Category Endothelium-Dependent Relaxing Factors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes			Y
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No					Y
Vero Biotech Inc	NOXIVENT	nitric oxide	GAS;INHALATION	207141-002	Oct 2, 2018	AA	RX	No	No

Market dynamics and patent landscape for drugs in MeSH “Endothelium-Dependent Relaxing Factors” (NLM)

Last updated: July 30, 2026

What drugs fall under NLM MeSH “Endothelium-Dependent Relaxing Factors,” and how do they make money?

Answer: The MeSH category maps to pharmacology centered on the endothelium-derived relaxing pathway, most commonly via nitric oxide (NO) signaling and downstream cGMP elevation, plus selected agents that modulate endothelial function or NO bioavailability. Commercially, the highest revenue exposure is concentrated in NO donors and cGMP-axis therapies, with additional revenue from NO-pathway modulators used in cardiovascular indications (and, depending on labeling geography and time, pulmonary hypertension).

Key commercial buckets by mechanism (typical MeSH overlap)

• NO donors / NO-release vasodilators
  • Organic nitrates (angina), nitric oxide inhalation (selected pulmonary indications)
  • Long-acting nitrate formulations with extensive generic penetration in many markets
• Soluble guanylate cyclase (sGC) stimulators
  • Pathway elevation of cGMP independent of upstream NO
• PDE5 inhibitors
  • cGMP degradation blockade; major global sales across multiple end-use indications
• Endothelin pathway agents
  • Indirectly related in pulmonary vascular disease programs; not strictly “endothelium-dependent relaxing factors,” but often co-addressed in PH and vascular remodeling landscapes
• NO synthase cofactors or endothelial function modifiers
  • Smaller commercial footprints; more often in niche or combination settings

Revenue dynamics that drive patent value

• Generic conversion pressure
  • Long-running nitrate products and early PDE5-inhibitor molecules face substantial erosion where Orange Book listings are thin or expiries are past.
• Lifecycle management
  • Most remaining patent “value pockets” are in:
    • next-generation formulations (extended-release, oral solubility, topical/transdermal)
    • fixed-dose combinations
    • pediatric exclusivities and method-of-use claims tied to specific regimens
• IP stacking vs. single-block analogs
  • In this pharmacologic space, estates survive longer when there is:
    • multiple layers of patents (compound + salt/form + formulation + method-of-use)
    • uninterrupted patent term extension (PTE) and pediatric exclusivity (where applicable)
    • regulatory exclusivities aligning with launch timing

Which patents protect NO-cGMP axis drugs for endothelial relaxation in the US, EU, and key geographies?

Answer: Protection typically concentrates in three layers: active ingredient claims, composition and formulation claims, and method-of-use/regimen claims. Where compounds are older (notably nitrates), protection often shifts to formulation and delivery systems or process claims. For newer cGMP-axis agents (sGC stimulators, next-gen NO donors), the estate is usually more compound-centered, often supported by narrower but still enforceable formulation and use patents.

Patent estate archetypes by drug class

1) Nitrates and NO donors

• Compound/salt patents: Usually expired for legacy molecules across major markets.
• Formulation and dosing patents: Core remaining enforceability for brands, including:
  • extended-release matrices
  • transdermal patches
  • specific dosing regimens for angina prophylaxis
• Manufacturing/process claims: Common when composition claims are weak or expired.

2) PDE5 inhibitors (cGMP degradation blockade)

• Compound patents: Expired for established molecules.
• Lifecycle claims that still matter:
  • salt/form and crystalline form patents (often time-limited)
  • combination therapy method-of-use (e.g., with cardiometabolic agents)
  • pediatric use patents and formulation variants (ODT, once-daily regimens)

3) sGC stimulators

• Compound + use + formulation tend to remain active longer in this category.
• Enforcement often hinges on:
  • specific titration or PH-related regimens
  • combination indications
  • manufacturing controls that preserve stability and bioavailability

Practical enforcement profile

• US: Orange Book-listed patents drive Paragraph IV leverage; non-Orange Book patents still support injunctions but require different litigation strategy.
• EU/UK: National enforcement can rely on EP family breadth plus local validation status.
• China/India: Product and process claims matter; local filing strategy often determines entry risk.

When does endothelium-dependent relaxing factor exclusivity end, and what timelines matter for generic entry?

Answer: Generic entry timing is dominated by the later of:

1. drug substance patent expiry
2. formulation/method-of-use patent expiry
3. regulatory exclusivity (where applicable)
4. any granted PTE/pediatric exclusivity
5. court stay/FTC settlement timelines after Paragraph IV

Typical timing stack (US)

• Patent expiry dates define the “hard stop” for Orange Book-listed claims.
• 180-day exclusivity for Paragraph IV first filers can create a post-expiry commercial delay even when patents expire.
• Settlement agreements frequently shift entry by delaying launch for non-admitted challengers.

Market impact pattern in this MeSH area

• When compound patents are gone, entry risk concentrates on method-of-use and formulation patents that remain later expiring.
• If the brand’s Orange Book list is short or narrow, generic sponsors may file to launch at the earliest date after claim workarounds.

What is the Orange Book status of drugs mapped to this MeSH category, and how is it used in Paragraph IV strategy?

Answer: Orange Book status is the primary map for Paragraph IV filings. In NO-cGMP axis therapeutics, the most commercially relevant Orange Book patents are those tied to:

• the approved strength/dosage form
• the claimed use in labeling
• the specific formulation (when a unique dosage form is used)

How Paragraph IV risk is assessed

• Is the patent listed for the same NDA/BLA and dosage form?
• Does the claim read on the generic product?
• Is there a usable “design-around” (different formulation/process or non-infringing method-of-use carve-out)?
• Has prior litigation narrowed claim construction for the family?

Litigation leverage points

• Brands favor Orange Book patents with:
  • clear claim scope aligned to the marketed regimen
  • strong infringement case (e.g., composition parameters)
  • sustained judicial deference due to prior PTAB outcomes or prosecution history

How many patents cover each leading drug, and which ones are most likely to block generic entry?

Answer: In this pharmacologic space, patent counts are rarely a reliable proxy for blocking power. The blocking assets are typically:

• Orange Book-listed formulation patents
• method-of-use patents that align to labeling
• combination therapy claims that cover co-administered regimens

What typically survives generic challenge

• Formulation patents that claim:
  • extended-release matrix structure
  • release profile parameters
  • particle size/crystal form
• Method-of-use patents that are drafted to match:
  • titration schedules
  • specific dosing frequency
  • combination partners included in indication language

What patent litigation affects NO-cGMP therapies and endothelial relaxing factor drugs?

Answer: Patent litigation in this category typically clusters around:

• Paragraph IV filings for branded PDE5 inhibitors, nitrate formulations, and sGC stimulators
• disputes over:
  • infringement of formulation/process claims
  • validity (novelty, obviousness)
  • enforceability (inequitable conduct, written description)
• settlement-driven entry timing that shifts generic launches by years.

Where settlements commonly land

• Brands and generic filers often structure:
  • a “launch date” tied to the next patent expiry
  • carve-outs or licensing for specific claim sets
  • additional payments if the generic delays further (state-dependent)

How do biosimilar risk and biologics factor into MeSH “Endothelium-Dependent Relaxing Factors”?

Answer: This MeSH class is overwhelmingly small molecule and pathway-modulating. Biosimilar risk is generally low because the core drugs in this pharmacologic mapping are not biologics.

What formulations are protected by patent in this therapeutic area?

Answer: Protected formulations in this MeSH space cluster around dosing, stability, and delivery:

Typical formulation protection targets

• Extended-release nitrates
  • matrix design and release kinetics
• Transdermal delivery
  • patch formulation and membrane-controlled release
• Oral solids and crystalline forms
  • polymorph/crystal form claims
• Dose-strength specific claims
  • patents tied to a particular strength or titration scheme
• Combinations
  • fixed-dose combinations with cardiometabolic agents where permitted by labeling

Which companies hold the most defensible patent estates in this MeSH area?

Answer: Patent ownership and defensibility are dominated by:

• original innovators behind PDE5 inhibitor successors, sGC stimulators, and next-gen NO donors
• brands that maintain Orange Book breadth via formulation and method-of-use patents

Competitive moat drivers

• Broad EP/US family coverage
• consistent prosecution across jurisdictions for key claims
• enforceable formulation IP that matches approved dosage forms
• litigation posture that discourages multiple challengers due to settlement economics

How does the competitive landscape compare across NO donors, sGC stimulators, and PDE5 inhibitors?

Answer: The competitive dynamics differ by how many layers of protection remain.

Comparative risk snapshot

• Legacy nitrates
  • high genericization across major markets
  • brand value depends on managed formulation niches and regional exclusivity
• PDE5 inhibitors
  • high competition for established molecules
  • remaining premium tied to newer regimens, formulations, or combination indications
• sGC stimulators
  • higher patent longevity relative to legacy molecules
  • entry risk tied to remaining compound and method-of-use/formulation assets

What generic entry risks exist for drugs in the “endothelium-dependent relaxing factors” pathway?

Answer: Generic entry risks rise when:

• Orange Book lists are short or expire soon
• method-of-use claims do not map tightly to current labeling
• the brand lacks formulation IP enforceability
• prior claim construction creates straightforward noninfringing workarounds

Entry playbook for generic sponsors

• File Paragraph IV to the earliest-listed patent that is both:
  • enforceable
  • likely to fail on validity/infringement in the district court

Brand playbook to reduce entry

• expand Orange Book coverage where legally permissible and properly tied to labeling
• secure stronger formulation claims with measurable release criteria
• pursue stays through settlement leverage

Key Takeaways

• “Endothelium-dependent relaxing factors” market exposure is dominated by NO-cGMP axis small molecules; biosimilar risk is not a primary driver.
• Patent blocking power depends less on total patent count and more on Orange Book-listed assets that match the approved dosage form and labeling use.
• Generic entry timing is governed by a stack of compound, formulation, method-of-use, and regulatory exclusivity, plus settlement- and Paragraph IV-related launch delays.
• The most defensible estates typically include formulation and regimen patents aligned to marketed strengths and dosing schedules.

FAQs

1. How do Orange Book-listed method-of-use patents for endothelial relaxing drugs influence Paragraph IV outcomes?
2. Do crystalline form or particle size patents meaningfully block generics for PDE5 inhibitors and nitrate formulations?
3. What settlement structures most commonly delay generic launch for cGMP-axis cardiovascular therapies?
4. Which regulatory exclusivities can extend market exclusivity for NO-cGMP drugs after patent expiry?
5. How do non-Orange Book patents (process or manufacturing controls) affect generic design-around strategies?

References

(No sources were provided in the prompt; no citations can be generated without external data.)